Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

Bin Su¹, Cheng Yao², Qing-Xia Zhao³, Wei-Ping Cai⁴, Min Wang⁵, Hong-Zhou Lu⁶, Yuan-Yuan Chen³, Li Liu⁶, Hui Wang⁷, Yun He⁷, Yu-Huang Zheng⁸, Ling-Hua Li⁹, Jin-Feng Chen⁴, Jian-Hua Yu⁴, Biao Zhu¹⁰, Min Zhao¹¹, Yong-Tao Sun¹², Wen-Hui Lun¹³, Wei Xia¹, Li-Jun Sun¹, Li-Li Dai¹, Tai-Yi Jiang¹, Mei-Xia Wang¹, Qing-Shan Zheng¹⁴, Hai-Yan Peng¹⁵, Yao Wang¹⁶, Rong-Jian Lu², Jian-Hua Hu², Hui Xing¹⁶, Yi-Ming Shao¹⁶, Dong Xie², Tong Zhang¹, Fu-Jie Zhang¹³, Hao Wu¹, for the TALENT Study Team

¹Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China; ²Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China; ³Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China; ⁴Infectious Disease Center, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China; ⁵Institute of HIV/AIDS, The First Hospital of Changsha, Hunan University, Hunan 410005, China; ⁶Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 200150, China; ⁷Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, Guangdong 518112, China; ⁸Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; ⁹Department of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, China; ¹⁰State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310005, China; ¹¹National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China; ¹²Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710038, China; ¹³Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China; ¹⁴Center for Drug Clinical Research, Shanghai university of Traditional Chinese Medicine, Shanghai 201203, China; ¹⁵Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China; ¹⁶State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100206, China.

Abstract
Background: Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.

Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2020;133(24)

Received: 25-06-2020 Edited by: Xin Chen and Peng Lyu
HIV-1 is an enveloped virus with 8 to 10 envelope “spike” complexes per virion, with two protein subunits, the surface subunit gp120 and the transmembrane subunit gp41, which mediate binding to receptors and viral entry by fusing cellular and viral membranes.\(^{20,21}\) The N- and C-terminal heptad repeat regions of the gp41 ectodomain refold into a thermostable six-helix bundle structure (6-HB), representing a fusion-active conformation, and offer an attractive target for developing antiviral agents.\(^{22,23}\) We have previously developed a novel HIV-1 fusion inhibitor, albuvirtide (ABT), a 3-Maleimidopropionic acid-modified peptide fusion inhibitor derived from the N-terminal sequence of HIV-1 gp41, which binds to the HIV-1 gp41 envelope protein.\(^{24}\) ABT exhibits broad-spectrum anti-HIV-1 activity in vitro, with a half maximal inhibitory concentration (IC\(_{50}\)) of 0.5 to 5.0 nmol/L. It has been shown to be active against 28 different clinical isolates of HIV-1 in China, with IC\(_{50}\) values ranging from 1.3 to 18.1 nmol/L.\(^{25}\) ABT also has a much longer half-life than the only viral fusion inhibitor approved by the Food and Drug Administration, enfuvirtide (T20, Fuzeon), which must be administered by twice-daily injections.\(^{26-28}\)

In phase 1 clinical studies, a single administration of ABT in HIV-1-infected adults was found to have a half-life of 10 to 12 days and to suppress viral replication for 6 to 10 days.\(^{29,30}\) In phase 2 clinical study, ABT was administered once weekly via the intravenous route, together with LPV/r. Treatment with this nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-free, two-drug regimen for seven weeks was well tolerated.\(^{29,31}\) The mean decrease in viral load in the 320 mg ABT group was 2.2 log\(_{10}\) copies/mL, with a margin of 12%. No ABT-related adverse effects, injection site reactions, or antibody generation were observed. Based on these results, we initiated a phase 3 pivotal trial to assess the safety, efficacy, and clinical practicality of a once-weekly ABT injection in treatment-experienced HIV-1-infected adults.

**Methods**

The Institutional Ethics Committee at each site reviewed and approved the protocol (No. 2013-067) and the written informed consent form which was provided according to the *Declaration of Helsinki*. Each patient gave written informed consent before undergoing the study procedures. The methods were carried out in accordance with approved guidelines and regulations.

**Ethics statement**

The Institutional Ethics Committee at each site reviewed and approved the protocol (No. 2013-067) and the written informed consent form which was provided according to the *Declaration of Helsinki*. Each patient gave written informed consent before undergoing the study procedures. The methods were carried out in accordance with approved guidelines and regulations.
**Study design and participants**

TALENT is an ongoing phase 3, open-label, randomized, multicenter, parallel-group, non-inferiority study in treat-ment-experienced adults with HIV-1 at 12 centers in China. Adults (aged 16–60 years) infected with HIV-1 were eligible for inclusion if they had a plasma viral RNA load of at least 1000 copies/mL or higher and had received at least 6 months of treatment with two classes of antiretroviral agents (NRTIs and non-nucleoside/nucleo-tide reverse transcriptase inhibitors [NNRTIs]). The exclusion criteria included active AIDS-defining condi-tions, prior exposure to protease inhibitors and fusion inhibitors, active hepatitis, abnormal values in standard laboratory tests (hemoglobin concentration <9 g/dL, white blood cell count <2 × 10^9/L, neutrophil count <1 × 10^9/L, platelet count <75 × 10^9/L, aminopherase levels more than 3 times the upper limit of the normal range, a total bilirubin concentration more than twice the upper limit of the normal range, creatinine concentration above the upper limit of the normal range, a creatine phosphokinase levels more than twice the upper limit of the normal range), serious chronic disease, hemophilia A or B, alcohol and/or drug abuse, and pregnancy and/or breastfeeding.

**Procedures**

Clinical case report form data were recorded electroni-cally for each patient and visit. Patients were randomly assigned (1:1) to either the ABT group or the NRTI group. The patients in the ABT group received 320 mg ABT daily for the first 3 days and then weekly by intravenous infusion, together with LPV/r (400 mg lopinavir, 100 mg ritonavir, twice daily). The patients in the NRTI group received LPV/r (same dose as above) plus two optimized NRTIs selected by the site investigator before randomiza-tion. For the NRTI group, if TDF had not been included in the first-line regimen, lamivudine (3TC, 300 mg daily) and TDF (300 mg, daily) were preferred. If TDF had been included in the first-line regimen, the acceptable alterna-tive NRTIs were: 3TC plus zidovudine (AZT, 300 mg, twice daily) or 3TC plus abacavir (ABC, 300 mg, twice daily) based on previous treatment experience and drug resistance.

Clinical examinations and laboratory analyses were conducted at the initial screening visit, at baseline (administration of study drugs), and at weeks 4, 12, 24, 36, and 48. CD4 T-cell count was measured at an accredited laboratory at each clinical site. The plasma HIV-1 RNA load was measured at a central laboratory in Beijing Youan Hospital, Capital Medical University. Genotype resistance was assessed at a laboratory in the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. Compliance with drug treatment was assessed at each visit. Adverse events were evaluated and graded according to the US NIH Division of AIDS toxicity scales. An independent data and safety monitoring board (DSMB) periodically reviewed the safety and efficacy results and made recommendations regarding completion of enrol-ment, interim analysis, and continuation of the study.

**Randomization and blinding**

Patients were allocated (1:1) to the ABT plus LPV/r group or the LPV/r plus two optimized NRTIs group. The randomization sequence was generated centrally by a computer via an interactive system accessible via a website or telephone. We used a block size of four. Site investigators checked the inclusion and exclusion criteria to confirm eligibility before the online group assignment and had access to the participant’s assignment details only once the checklists had been completed. The viral assay was performed in an accredited central laboratory, and the laboratory personnel were blind to the treatment group. The participants and other onsite personnel were not blind to the treatment group.

**Outcomes**

The primary objective of this study was to determine whether the efficacy of ABT plus LPV/r was non-inferior to standard second-line regimens containing LPV/r and two NRTIs. We performed a modified intention-to-treat (mITT) analysis of efficacy, including data for all patients who received at least one dose of the study drug and underwent HIV-1 RNA load testing at least once after treatment.

The per-protocol analysis included patients who received the study drugs for 24 or 48 weeks, with no major protocol violation. The primary endpoint was the proportion of patients achieving plasma HIV-1 RNA levels of fewer than 50 copies/mL at week 48. For the primary analysis, the virological response was assessed with the snapshot algorithm defined by the US FDA. This algorithm scores efficacy based on a snapshot of HIV-1 RNA levels at particular weeks, with a missing-as-failure analysis (missing data for HIV-1 RNA considered to be >50 copies/mL). The secondary endpoints included the proportion of patients with plasma HIV-1 RNA levels below 400 copies/mL, changes from baseline in HIV-1 RNA log_{10} copies/mL, and CD4 T-cell counts.

The safety data were analyzed up to week 48 for all patients receiving at least one dose of the study drug. The main safety endpoints were the incidence and severity of adverse events and changes in laboratory parameters.

**Statistical analysis**

The primary efficacy hypothesis was that ABT would display antiviral activity non-inferior to that of NRTI at week 48 if both treatments were administered in combination with LPV/r. The non-inferiority margin was prespecified as 12%, based on applicable HIV-1-specific and statistical guidelines. The treatment was considered non-inferior if the lower limit of the two-tailed 95% confidence interval (CI) for the difference in the proportion of patients with plasma HIV-1 RNA levels below 50 copies/mL at week 48 was −12% or greater. The aim was to test for superiority at a nominal significance level of 5% if non-inferiority was established in both the mITT and per-protocol analyses. Assuming a virological success rate of 80% in both groups and a dropout rate of...
20%, we would need to include 420 patients to achieve 80% power in the two-tailed test, with an alpha risk of 5%, for the demonstration of non-inferiority for the primary endpoint.

We used SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) for all statistical analyses. An interim analysis was specified in advance in the study protocol and was performed in accordance with the recommendations of the DSMB.

Results

Between February 11, 2014, and December 5, 2015, we enrolled 347 participants. At the time of the interim analysis, 208 had completed the 24-week visit and the data for these patients are reported here. On July 1, 2015, one site was closed due to a serious protocol violation; consequently, nine patients from this site were excluded from the efficacy analysis [Figure 1].

The study treatments, baseline characteristics, previous treatment drugs, and genotypic resistance profile of the participants were distributed similarly between the two groups [Table 1]. Other than the baseline characteristics of HIV-1-infected patients summarized in Table 1, most of the patients were infected with HIV-1 subtype B (50.9%) viruses, with CRF01_AE viruses being the next most common (29.6%). In accordance with NFATP guidelines, 54.3% of the patients received AZT and 44.0% received TDF in their first-line treatment regimens. On entry into the study, the first-line nucleoside analog was switched from AZT to TDF, according to WHO guidelines for second-line treatment, or from other nucleoside drugs to TDF. Baseline genotypic resistance to at least one ART drug was observed in 81.7% of patients, with resistance to efavirenz (79.9%), nevirapine (79.9%), and lamivudine (67.5%) being the most frequently recorded (datatable not shown). Major protease inhibitor mutations were rare (1.2%), and none of those detected were expected to affect the susceptibility to LPV/r. In addition, using the baseline genotypic resistance data, we assessed the sensitivity of the viruses to the switched nucleoside inhibitor in the NRTI group; the virus was sensitive in 69.7% of cases and highly resistant in 12.4% (datatable not shown).

At week 48, 37 (80.4%) of the 46 subjects in the ABT and 33 (66.0%) of the 50 subjects in the NRTI group had HIV-1 RNA levels of fewer than 50 copies/ml [Table 2 and Figure 2A]. There was a 14.4% difference between the treatments, with a 95% CI of −3.0 to 31.9, meeting the criteria for non-inferiority. We also concluded that ABT was non-inferior at week 24 when 66 (79.5%) of the 83 subjects in the ABT group and 72 (78.3%) of the 92 subjects in the NRTI group had HIV-1 RNA levels of fewer than 50 copies/mL (difference of 1.2%, 95% CI: −10.8% to 13.2%).
The results of the secondary and primary efficacy analyses were consistent [Table 2]. CD4+ T-cell counts increased from baseline to week 48 in both groups (a median change of 120.5 cells/µL in the ABT group; 150.3 cells/µL in the NRTI group, \(P = 0.557\)).

We assessed the development of resistance mutations in patients whose viral load was >400 copies/mL at weeks 24 or 48: five patients from the ABT group and 13 patients from the NRTI group. NRTI resistance mutations (M41L and T215F) that had emerged since baseline were noted in one patient from the ABT group, whereas the M184V, M41LM, and K70KR mutations were observed in three patients from the NRTI group. NRTI resistance mutations (M41L and V82A) and minor protease resistance mutations (L33F, H221Y) emerged in only one patient from the NRTI group. NNRTI resistance mutations (Y181C and K70KR) mutations were observed in three patients from the NRTI group. NRTI resistance mutations (M41L and V82A) and minor protease resistance mutations (L33F, H221Y) emerged in only one patient from the NRTI group. One patient in the NRTI group developed both major (I50V and V82A) and minor protease resistance mutations (L33F, H221Y).
Q58E, and L10F). The minor protease resistance mutations L10I and A71AV were also detected in two patients from the ABT group, and the A71AT mutation was found in one patient from the NRTI group. None of the five patients in the ABT group developed resistance mutations of the gp41 gene after baseline.

Self-reported compliance/adherence to treatment was similar between the two groups. In the ABT group, 100% of patients had compliance levels of 90% to 110% for all study drugs over the treatment period. The corresponding value for the NRTI group was 96.7%.

Safety profiles were similar for the two groups, with similar rates of adverse events [Table 3], most of which were of mild to moderate intensity. Grade 3 to 4 adverse event frequencies were similar in the two groups (14.0% vs. 11.1%). The most common adverse events were diarrhea (8.6% vs. 14.1%, ABT vs. NRTI), upper respiratory tract infections (4.3% vs. 6.1%), and grade 3 to 4 increases in triglyceride concentration (6.5% vs. 4.0%).

Renal function was significantly more strongly impaired at 12 weeks in the patients of the NRTI group receiving TDF than in those of the ABT group (mean change in estimated glomerular filtration rate: –11.48 vs. –1.22 mL·min⁻¹·1.73 m⁻², \( P = 0.02 \)) [Figure 3]. Safety events leading to treatment discontinuation (adverse events or stopping criteria) were infrequent in both treatment groups [Figure 1]. The rates and nature of the serious adverse events observed were also similar, and few patients developed a drug-related serious adverse event [Table 3]. No deaths occurred. The distribution and number of graded treatment-emergent laboratory toxicities were similar between groups [Table 3].

### Table 3: Clinical adverse events and laboratory abnormalities.

| Parameters                              | ABT group (\( N = 93 \)) | NRTI group (\( N = 99 \)) |
|-----------------------------------------|---------------------------|---------------------------|
| Grade 3–4 adverse events                | 13 (14.0)                 | 11 (11.1)                 |
| Serious adverse events                  | 6 (6.5)                   | 3 (3.0)                   |
| Drug-related serious adverse events     | 0 (0.0)                   | 1 (1.0)                   |
| Clinical adverse events in \( \geq 2\% \) of patients in either group |                          |                           |
| Pharyngitis                             | 3 (3.2)                   | 1 (1.0)                   |
| Tonsillitis                             | 2 (2.2)                   | 0 (0.0)                   |
| Upper respiratory tract infection       | 4 (4.3)                   | 6 (6.1)                   |
| Pulmonary infection                     | 0 (0.0)                   | 2 (2.0)                   |
| Urethritis                              | 2 (2.2)                   | 1 (1.0)                   |
| Gastroenteritis                         | 0 (0.0)                   | 5 (5.1)                   |
| Enteritis                               | 2 (2.2)                   | 0 (0.0)                   |
| Diarrhea                                | 8 (8.6)                   | 14 (14.1)                 |
| Fever                                   | 2 (2.2)                   | 3 (3.0)                   |
| Fatigue                                 | 2 (2.2)                   | 0 (0.0)                   |
| Peripheral edema                        | 0 (0.0)                   | 2 (2.0)                   |
| Rash                                    | 2 (2.2)                   | 2 (2.0)                   |
| Haematuria                              | 1 (1.1)                   | 4 (4.0)                   |
| Headache                                | 2 (2.2)                   | 0 (0.0)                   |
| Dizzy                                   | 2 (2.2)                   | 0 (0.0)                   |
| Grade 3–4 laboratory abnormalities in \( \geq 2\% \) of patients in either group |                          |                           |
| High triglycerides                      | 6 (6.5)                   | 4 (4.0)                   |
| High total cholesterol                  | 1 (1.1)                   | 2 (2.0)                   |
| High hemoglobin                        | 0 (0.0)                   | 2 (2.0)                   |
| Hepatic function disorder\(^*\)         | 2 (2.2)                   | 1 (1.0)                   |

Data are \( n \) (%). *Two or three items increased among aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase. ABT: Albuvirtide; NRTI: Nucleoside/Nucleotide reverse transcriptase inhibitor.
therefore, antiviral drugs targeting the pocket are expected to have potent and broad anti-HIV-1 activity against diverse HIV-1 strains and a high genetic barrier for drug resistance. A previous study showed that treatment resistance has emerged in patients who fail T20-containing regimens. However, an in vitro study demonstrated that ABT has potent and broad anti-HIV-1 activity not only against currently circulating subtypes worldwide but also against the induced variants that are resistant to T20.

Of note, in our TALENT study, although five patients whose viral load was >400 copies/mL at weeks 24 and 48 in the ABT group were assessed for the development of resistance mutations, none of them developed resistance mutations of gp41 after baseline. These findings suggest that the novel fusion inhibitor ABT has a higher potency than T20 and exhibits a higher genetic barrier for drug resistance.

A strength of ABT is that it can irreversibly conjugate with serum albumin, thus prolonging the half-life of 10 to 12 days, indicating that it could be suitable for once-weekly and less frequent dosing intervals. Therefore, this long half-life of ABT has the potential to improve adherence to therapy, allow a more forgiving time window of drug administration, and even significantly reduce the cost of treatment.

In the previous phase 2 study, ABT was well tolerated by patients, and there were no serious adverse events during the 47 days of treatment. In the present study, we found that the profile and frequency of grade 3 to 4 adverse events with long-term ABT treatment were similar to those of the NRTI group [Table 3]. The most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Moreover, renal function was significantly less impaired at 12 weeks in the patients in the ABT group than those in the NRTI group who received TDF [Figure 3]. Thus, long-term treatment (48 weeks) with ABT/LPV/r showed potent efficacy in HIV-1-infected patients, without an increased rate of adverse events.

In conclusion, this phase 3 clinical trial showed that the injectable long-acting HIV-1 drug ABT combined with LPV/r is both safe and effective. Compared with regimens of 3 to 4 drugs, the two-drug regimen offers a simplified therapy with better safety, less drug-drug interaction, and fewer patients who develop a drug-related serious adverse event. This interim analysis indicates that once-weekly ABT in combination with LPV/r is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure. Although investigational long-acting ART may allow HIV-1-infected patients who have difficulty with daily oral therapy to maintain viral suppression, with long-acting therapies, these patients and their retention in care should be closely monitored to avoid risk for the emergence of resistance to treatment.

Acknowledgements

The authors thank all members of the TALENT team; they were responsible for study oversight and played important roles in the study at their sites; cared for our patients...
before, during, and following this study; and provided input as well as intellectual and other valuable contributions. The authors greatly appreciate and acknowledge their patient described herein for volunteering his time and for donating numerous samples that allowed the detailed analyses to be performed. In addition, the authors are grateful to Dr. Christine Karlama (Hospital Pitie Salpêtrière, Paris, France) and Dr. Christiane Moog (INSERM U1109, Strasbourg, France) for the helpful discussions and critical evaluation of this manuscript.

**Funding**

This work was supported by the Frontier Biotechnologies Inc., Ministry of Science and Technology of China (Nos. 2013ZX09101001 and 2017ZX09201007), the Beijing Municipal of Science and Technology Major Project (Nos. D141100000314005, D141100000314002, and D161100000416003), the National Natural Science Foundation of China (Nos. 81772165, 81974303, and 81571973), and Beijing Key Laboratory for HIV/AIDS Research (No. BZ0089).

**Conflicts of interest**

The authors of this manuscript have read the journal's policy and have the following competing interests: CY, RJL, JHH, and DX have received salary support from Frontier Biotechnologies Inc. All authors had full access to all study data and analyses and approved the final report. All other authors have declared that no competing interests exist.

**References**

1. AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018). Chin J Intern Med 2018;57:1–18. doi: 10.3760/cma.j.issn.0578-1426.2018.12.002.

2. Joint United Nations Programme on HIV/AIDS (UNAIDS), Switzerland. 90-90-90 An ambitious treatment target to help end the AIDS epidemic; October 2014. Available from: https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf.

3. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012;156:817–833. doi: 10.7326/0003-4819-156-11-201206030-00419.

4. Joint United Nations Programme on HIV/AIDS (UNAIDS), UNAIDS data 2020, 2020. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf.

5. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treatment and Preventing HIV Infection Recommendations for a Public Health Approach, Second edition. Geneva, Switzerland: World Health Organization; 2016.

6. World Health Organization. Guidelines on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV, WHO Guidelines Approved by the Guidelines Review Committee 2015.

7. Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA 2016;316:191–210. doi: 10.1001/jama.2016.8900.

8. Joint United Nations Programme on HIV/AIDS (UNAIDS), Global HIV & AIDS statistics — 2020 fact sheet, 2020. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_Fact_Sheet_en.pdf.

9. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV; July 10, 2019. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.

10. Prabhu S, Harwell JL, Kumaraswamy N. Advanced HIV: diagnosis, treatment, and prevention. Lancet HIV 2019;6:e340–e351. doi: 10.1016/S2352-3018(19)30189-4.

11. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Global HIV/AIDS Epidemic, 2019. Available from: https://www.unaids.org/en/resources/fact-sheet.

12. NCAIDS, NCSTD, China CDC. Update on the AIDS/STD epidemic in China the third quarter of 2018. Chin J AIDS STD 2018;24:1075. doi: 10.15419/j.cjasts.2018.11.014.

13. Wu P, Tang Z, Lan G, Qian H, Chen H, You Y, et al. Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program. Sci Rep 2018;8:3431. doi: 10.1038/s41598-018-21791-2.

14. Zhang F, Doss Z, Ma Y, Zhang Y, Zhao Y, Zhao D, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011;11:516–524. doi: 10.1016/S1473-3099(11)70097-4.

15. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, Zhao D, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS 2007;21 Suppl 8:s143–s148. doi: 10.1097/01.aids.0000304710.10036.2b.

16. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China’s free ART program. Cell Res 2015;15:877–882. doi: 10.1038/sj.cr.7290362.

17. Xu B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, et al. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol 2019;10:1472. doi: 10.3389/fphar.2019.01472.

18. AIDS Professional Group, Society of Infectious Diseases, Chinese Medical Association. Third Edition of the Guidelines for Diagnosis and Treatment of HIV/AIDS, Chinese Journal of Infections Diseases 2015;5:385–401. doi: 10.3760/cma.js.issn1674-2937.2015.05.001.

19. Wu ZY, Scott SR. Human immunodeficiency virus prevention strategies in China. Chin Med J 2020;133:318–325. doi: 10.1097/CM9.0000000000006647.

20. Zhu P, Chertova E, Bess J Jr, Liason JD, Arthur LO, Liu J, et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immuno deficiency virus virions. Proc Natl Acad Sci U S A 2003;100:15812–15817. doi: 10.1073/pnas.2634931100.

21. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681–684. doi: 10.1016/S0092-8674(00)81430-9.

22. Lu L, Yu F, Cai L, Debnath AK, Jiang S. Development of small-molecule HIV entry inhibitors specifically targeting gp120 or gp41. Curr Top Med Chem 2016;16:1074–1090. doi: 10.2174/1568026615666150901114527.

23. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 1998;95:15613–15617. doi: 10.1073/pnas.95.26.15613.

24. Xie D, Yao C, Wang L, Min W, Xu J, Xiao J, et al. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 2010;54:191–196. doi: 10.1128/AAC.00976-09.

25. Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, et al. Biophysical property and broad anti-HIV activity of albumivir, a 3-naleimidomidopropionic acid-modified peptide fusion inhibitor. PLoS One 2012;7:e32599. doi: 10.1371/journal.pone.0032599.

26. Lazzarin A, Clotet B, Cooper D, Reyes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186–2195. doi: 10.1056/NEJMoa0335211.

27. Lalezari JP, Henry K, O’Hearn M, Montaner JS, Pierno PJ, Trotter B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–2185. doi: 10.1056/NEJMoa035026.

28. Jiang S, Lan K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993;365:113. doi: 10.1038/365113a0.

29. Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, et al. Combination of long-acting HIV fusion inhibitor albumivir and...
LPV/r showed potent efficacy in HIV-1 patients. AIDS Res Ther 2016;13:8. doi: 10.1186/s12981-016-0091-1.

30. Wu H, Yao C, Lu RJ, Zhang T, Wang MX, Zhao HX, et al. Albuvirtide, the First Long-acting HIV Fusion Inhibitor, Suppressed Viral Replication in HIV-Infected Adults. 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC) 2012, Abstract H-554.

31. Yang W, Xiao Q, Wang D, Yao C, Yang J. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results. Xenobiotica 2017;47:133–143. doi: 10.3109/00498254.2016.1166532.

32. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005;44:175–186. doi: 10.2165/00003088-200544020-00003.

33. Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 2013;123:3848–3860. doi: 10.1172/JCI67399.

34. Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, et al. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scand J Infect Dis 2011;43:373–379. doi: 10.3109/00365548.2011.532320.

How to cite this article: Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Xua W, Sun LJ, Dau LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Lu RJ, Hu JH, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J 2020;133:2919–2927. doi: 10.1097/CM9.0000000000001273